Shareholder Action Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles - (NewMediaWire) - January 3, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 9, 2020 and December 8, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before February 18, 2022.         

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. The FDA raised concerns about the validity of Reata’s clinical study design trials to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome. This created a significant risk that the FDA would not approve the Company’s NDA. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Reata, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

 

SOURCE:

The Schall Law Firm

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.